0000899243-22-036303.txt : 20221117
0000899243-22-036303.hdr.sgml : 20221117
20221117211212
ACCESSION NUMBER: 0000899243-22-036303
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221116
FILED AS OF DATE: 20221117
DATE AS OF CHANGE: 20221117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nacht Mariana
CENTRAL INDEX KEY: 0001831310
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38707
FILM NUMBER: 221400366
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVENUE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664106
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471514975
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 HAYDEN AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-245-0399
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVE
STREET 2: 2ND FLOOR
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-16
1
0001664106
LogicBio Therapeutics, Inc.
LOGC
0001831310
Nacht Mariana
C/O LOGICBIO THERAPEUTICS, INC.
65 HAYDEN AVE, FLOOR 2
LEXINGTON
MA
02421
0
1
0
0
Chief Scientific Officer
Stock Option (right to buy)
0.70
2022-11-16
4
D
0
100000
D
2032-03-01
Common Stock
100000
0
D
The options were granted on March 1, 2022. The options were scheduled to vest over four years: 25% of the options were scheduled to vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the LogicBio Therapeutics, Inc. (the "Company") on each vesting date.
Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.
/s/ Frederic Chereau, as Attorney-in-Fact
2022-11-17